Eco Animal Health ( (GB:EAH) ) has shared an update.
ECO Animal Health Group has sold certain non-core product lines, specifically ECOmectin licenses for sheep and cattle in Southern Africa, to a distribution partner for £491,000. This strategic move allows the company to sharpen its focus on its core business of pigs and poultry, reinvesting the proceeds into its R&D pipeline for new vaccines and preventatives, and potentially a share buy-back, subject to shareholder approval, to satisfy future employee share incentives.
More about Eco Animal Health
ECO Animal Health is a global leader in animal health, specializing in the development and marketing of branded veterinary pharmaceuticals, particularly antibiotics and vaccines for pigs and poultry. Headquartered in the UK, the company operates globally with marketing authorizations in over 70 countries, employing more than 200 people worldwide. Its flagship product, Aivlosin®, is a patented medication effective in treating respiratory and intestinal diseases in pigs and poultry.
YTD Price Performance: -17.61%
Average Trading Volume: 53,872
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £39.64M
See more data about EAH stock on TipRanks’ Stock Analysis page.